Futureco Bioscience

At the core of this agreement is a novel biocontrol product, based on the proprietary strain B2017 of Pseudomonas alloputida.

This innovation leverages the potent nematicide activity of strain B410 of Metabacillus halosaccharovorans.

The Brazilian subsidiary expands the company’s network, which already includes four subsidiaries in Peru, Mexico, Colombia, and Costa Rica.

The opening is part of the company’s LATAM expansion strategy and follows in recent successes in Mexico and Peru.

BestCure is now ready to be marketed in Mexico, where it had already completed the registration stage.